Summary
Medtronic plc (MDT) reported its financial results for the six months ended October 30, 2015, a period significantly impacted by the acquisition of Covidien plc on January 26, 2015. This acquisition led to a substantial increase in net sales, up 66% to $14.332 billion compared to the prior year's six-month period. However, net income decreased by 21% to $1.340 billion, primarily due to a significant tax adjustment related to the internal reorganization of legacy Covidien businesses. Diluted earnings per share also saw a decline from $1.70 to $0.94. The company's operating segments, particularly the newly formed Minimally Invasive Therapies Group (largely comprising Covidien's former operations), significantly contributed to the revenue growth. Despite the revenue surge, increased costs, including higher cost of products sold and amortization of intangible assets, along with restructuring charges and acquisition-related expenses, impacted profitability on a GAAP basis. Management also highlighted the impact of foreign currency fluctuations, which had an unfavorable effect on net sales.
Financial Highlights
51 data points| Revenue | $7.06B |
| Cost of Revenue | $2.18B |
| Gross Profit | $4.88B |
| SG&A Expenses | $2.34B |
| Operating Income | $1.30B |
| Interest Expense | $324.00M |
| Net Income | $520.00M |
| EPS (Basic) | $0.37 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 1.41B |
| Shares Outstanding (Diluted) | 1.43B |
Key Highlights
- 1Net sales increased by 66% year-over-year to $14.332 billion for the six months ended October 30, 2015, largely driven by the acquisition of Covidien.
- 2Net income decreased by 21% to $1.340 billion for the six months ended October 30, 2015, mainly impacted by a $442 million tax charge related to an internal reorganization.
- 3Diluted earnings per share decreased to $0.94 from $1.70 for the comparable six-month periods.
- 4The acquisition of Covidien led to the creation of the Minimally Invasive Therapies Group, which significantly contributed to revenue.
- 5Operating profit before taxes decreased by 4% to $2.023 billion for the six months ended October 30, 2015, despite higher revenues.
- 6Amortization of intangible assets increased substantially from $176 million to $964 million due to the Covidien acquisition.
- 7The company maintained a strong cash flow from operations of $2.095 billion for the six months ended October 30, 2015, with free cash flow at $1.649 billion.